Rituximab as maintenance treatment for systemic Lupus ErythematosusA multicentre observational study of 147 patients

ConclusionsRMT is a potential treatment option in difficult to treat patients. Relapses occur during RMT and are more likely in those with active articular disease at the time of the first RTX. Relapse risk after RMT remains high and apparently comparable to the one seen after a single ‐RTX course.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - May 17, 2019 Category: Rheumatology Authors: Matthias A. Cassia, Federico Alberici, Rachel B. Jones, Rona M. Smith, Giovanni Casazza, Maria L. Urban, Giacomo Emmi, Gabriella Moroni, Renato A. Sinico, Piergiorgio Messa, Frances Hall, Augusto Vaglio, Maurizio Gallieni, David R. Jayne Tags: Full Length Source Type: research